Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest
Highlights of AbbVie’s Q1 2024 financial results
Categories
biotech & pharma
Veru Inc (VERU) Q2 2023 Earnings Call Transcript
Veru Inc (NASDAQ:VERU) Q2 2023 Earnings Call dated May. 11, 2023. Corporate Participants: Samuel Fisch -- Executive Director of Investor Relations and Corporate Communications
PetIQ, inc (PETQ) Q1 2023 Earnings Call Transcript
PetIQ, inc (NASDAQ: PETQ) Q1 2023 Earnings Call dated May. 09, 2023 Corporate Participants: Katie Turner -- Investor Relations Cord Christensen --
Merck & Co., Inc. (MRK) Q1 2023 Earnings Call Transcript
Merck & Co., Inc. (NYSE: MRK) Q1 2023 Earnings Call dated Apr. 27, 2023 Corporate Participants: Peter Dannenbaum -- Vice President, Investor Relations Robert
RVL Pharmaceuticals plc (RVLP) Q4 2022 Earnings Call Transcript
RVL Pharmaceuticals plc (NASDAQ: RVLP) Q4 2022 earnings call dated Mar. 20, 2023 Corporate Participants: Lisa Wilson -- Investor Relations Brian Markison -- Chief Executive Officer
Corcept Therapeutics Incorporated (CORT) Q4 2022 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2022 Earnings Call dated Feb. 28, 2023. Corporate Participants: Atabak Mokari -- Chief Financial Officer Charles Robb -- Chief Business Officer
PetIQ Inc (PETQ) Q4 2022 Earnings Call Transcript
PetIQ Inc (NASDAQ:PETQ) Q4 2022 Earnings Call dated Feb. 28, 2023. Corporate Participants: Katie Turner -- Investor Relations McCord Christensen -- Chief Executive Officer and Chairman
Moderna Inc (MRNA) Q4 2022 Earnings Call Transcript
Moderna Inc (NASDAQ:MRNA) Q4 2022 Earnings Call dated Feb. 23, 2023. Corporate Participants: Lavina Talukdar -- Head of Investor Relations Stephane Bancel -- Chief Executive Officer
Merck & Co Inc (MRK) Q4 2022 Earnings Call Transcript
Merck & Co Inc (NYSE:MRK) Q4 2022 Earnings Call dated Feb. 02, 2023. Corporate Participants: Peter Dannenbaum -- Vice President, Investor Relations Robert M.